Open an account

Rapport Therapeutics

RAPP · NASDAQ

$29.37+$0.77 (+2.69%)TodayMarket closed ·
Prev close $28.60

About RAPP

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Employees
84
Headquarters
Boston, Massachusetts
Listed
Jun 7, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
rapportrx.com

RAPP key statistics

Market cap
1.37B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
432.76K
Volume
4.93M
Open price
$30.33
High today
$31.31
Low today
$26.73
52 Week high
$52.93
52 Week low
$23.75

Rapport Therapeutics (RAPP) at a glance

Rapport Therapeutics (RAPP) last traded at $29.37, with a market cap of 1.37B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $26.73 and $31.31. The current price is 9.9% above the day's low and 6.2% below its high.

Volume so far is 4.93M shares, above the average of 432.76K shares a day.

Over the past year Rapport Therapeutics has ranged from $23.75 to $52.93, and now sits 19% of the way up that range.

Rapport Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.19 per share against an estimate of -$0.9733.

The average analyst price target is $62.87, 114.1% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $62.87
Low
$50.50
Now
$29.37
High
$84.00

RAPP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 16.4% on average.

  1. Q3 FY24: reported -$0.50 per share against an estimate of -$0.5875
  2. Q4 FY24: reported -$0.57 per share against an estimate of -$0.6375
  3. Q1 FY25: reported -$0.68 per share against an estimate of -$0.7752
  4. Q2 FY25: reported -$0.75 per share against an estimate of -$0.8483
  5. Q3 FY25: reported -$0.71 per share against an estimate of -$0.7909
  6. Q4 FY25: reported -$0.72 per share against an estimate of -$0.6916
  7. Q1 FY26: reported -$0.42 per share against an estimate of -$0.6842
  8. Q2 FY26: reported -$1.19 per share against an estimate of -$0.9733

RAPP news

  • Vandana Singh

    Why Is Rapport Therapeutics Stock Trading Higher Today?

  • Press releaseGlobe Newswire

    Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

  • Avi Kapoor

    Gold Moves Higher; Robinhood Shares Jump

  • Avi Kapoor

    Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday

  • Avi Kapoor

    Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results

  • Vandana Singh

    Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year

  • Market-Moving News for September 8th

  • Press releaseBusiness Wire

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Similar companies

Companies in the same industry as Rapport Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.